犬异位性皮肤炎市场 - 全球产业规模、份额、趋势、机会和预测，按产品、按给药方式、按配销通路、按地区和竞争细分，2020-2030 年预测

2024 年全球犬异位性皮肤炎市场价值为 9.956 亿美元，预计将经历强劲增长，2024 年至 2030 年的年复合成长率(CAGR) 为 9.90%。该市场涵盖与犬异位性皮肤炎的诊断、治疗和管理相关的产品和服务，犬异位性皮肤炎是一种常见的皮肤病，会引起搔痒、发炎和不适。市场包括各种旨在缓解症状和改善患病狗生活品质的疗法和治疗方法。根据宠物食品製造商协会（PFMA）的最新资料，预计到 2022 年英国将拥有 3,490 万隻宠物，其中包括 1,300 万隻狗。宠物数量的增加凸显了对高级兽医护理的需求不断增长，这推动了兽医专业人员在皮肤病方面的专业化，凸显了人们对全面宠物医疗保健服务的日益关注。

主要市场驱动因素：

主要市场挑战：

主要市场趋势：

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球犬异位性皮肤炎市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（糖皮质激素、抗组织胺、免疫抑制剂、单株抗体、其他）
  • 依给药方式分类（外用、口服、注射）
  • 按配销通路（兽医院/诊所、零售、电子商务）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 按产品
  • 按管理方式
  • 按配销通路
  • 按地区

第 6 章：北美犬异位性皮肤炎市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲犬异位性皮肤炎市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太犬异位性皮肤炎市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美犬异位性皮肤炎市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲犬异位性皮肤炎市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Zoetis Inc
• Elanco Animal Health Inc
• Virbac SA
• Toray Industries Inc
• AB Science SA
• Boehringer Ingelheim GmbH
• Kindred Biosciences Inc

第 15 章：策略建议

第16章调查会社について・免责事项

The global Canine Atopic Dermatitis Market was valued at USD 995.60 million in 2024 and is projected to experience robust growth, with a compound annual growth rate (CAGR) of 9.90% from 2024 to 2030. This market encompasses products and services related to the diagnosis, treatment, and management of atopic dermatitis in dogs-a common skin condition that causes itching, inflammation, and discomfort. The market includes various therapies and treatments aimed at alleviating symptoms and improving the quality of life for affected dogs. According to recent data from the Pet Food Manufacturers' Association (PFMA), the United Kingdom was expected to have 34.9 million pets in 2022, including 13 million dogs. This rising pet population underscores the increasing demand for advanced veterinary care, which has driven the specialization of veterinary professionals in dermatological conditions, highlighting the growing focus on comprehensive pet healthcare services.

Key Market Drivers:

Rising Pet Ownership and Humanization: The global pet industry has seen significant growth, largely due to an increasing number of pet owners worldwide. Along with this trend, pets are increasingly being regarded as family members rather than just companions, a shift that has major implications for various pet-related markets, including the canine atopic dermatitis market. The 2021-2022 American Pet Products Association (APPA) National Pet Owners Survey revealed that dog owners spent an average of USD 458 on surgical veterinary visits and USD 242 on routine visits. This growing investment in pet health, combined with increasing awareness of canine health issues, is driving demand for advanced treatments, including those for conditions such as canine allergic dermatitis, thereby fostering growth in the veterinary care market. In particular, the rise in pet ownership has led to increased demand for healthcare products and services, including treatments for chronic conditions like atopic dermatitis. As pets are increasingly seen as family members, pet owners are more likely to prioritize high-quality healthcare, including preventive measures and ongoing management of conditions such as canine atopic dermatitis.

Key Market Challenges:

Misdiagnosis and Underdiagnosis: A key challenge in managing canine atopic dermatitis is the potential for misdiagnosis or underdiagnosis. Symptoms such as itching, redness, and skin irritation often overlap with other skin conditions, making accurate diagnosis essential. Failing to identify atopic dermatitis can result in improper treatments or a lack of intervention, potentially worsening the dog's condition.

Varied Triggers: Canine atopic dermatitis has various triggers, including environmental allergens, food sensitivities, and genetic factors. Identifying the specific trigger for each dog can be challenging, which makes developing a universal treatment plan difficult. This variability requires a personalized approach to treatment and care.

Compliance and Duration of Treatment: Ensuring compliance with prescribed treatment regimens over the long term can be a challenge for both pet owners and veterinarians. The ongoing nature of the condition necessitates sustained management, which may impact adherence to prescribed therapies.

Key Market Trends:

Advancements in Immunotherapy: Allergen-specific immunotherapy (ASIT) is becoming more refined and accessible. The development of more accurate allergy testing methods and innovative ASIT treatments is expected to enhance the management of atopic dermatitis by targeting the specific allergens that cause the condition in each dog.

Targeted Therapies: Pharmaceutical advancements are leading to the development of targeted therapies that address the underlying causes of canine atopic dermatitis. These treatments aim to reduce the need for long-term symptom management, ultimately improving the quality of life for affected dogs.

Holistic and Alternative Therapies: Holistic and alternative treatments, such as acupuncture, herbal remedies, and physical rehabilitation, are gaining popularity as complementary options for managing atopic dermatitis. These approaches are being recognized for their potential to improve overall well-being and provide additional management options for pet owners seeking non-traditional therapies.

Key Market Players:

• Zoetis Inc.
• Elanco Animal Health Inc.
• Virbac SA
• Toray Industries Inc.
• AB Science SA
• Boehringer Ingelheim GmbH
• Kindred Biosciences Inc.

Report Scope:

This report segments the global Canine Atopic Dermatitis Market into multiple categories, providing valuable insights into industry trends and forecasts. The market is segmented as follows:

By Product:

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• Monoclonal Antibodies (MAbs)
• Others

By Mode of Administration:

• Topical
• Oral
• Injectable

By Distribution Channel:

• Veterinary Hospitals/Clinics
• Retail
• E-commerce

By Region:

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain
• Asia-Pacific: China, Japan, India, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape:

This section offers a detailed analysis of the major players operating in the global Canine Atopic Dermatitis Market.

Available Customizations:

TechSci Research provides customization options for this market report based on specific company requirements. Customization options include detailed profiles of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Canine Atopic Dermatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 5.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 5.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Mode of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Canine Atopic Dermatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 6.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 6.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Canine Atopic Dermatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Mode of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Canine Atopic Dermatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Mode of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Canine Atopic Dermatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Mode of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Canine Atopic Dermatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 7.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 7.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Canine Atopic Dermatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Mode of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Canine Atopic Dermatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Mode of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Canine Atopic Dermatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Mode of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Canine Atopic Dermatitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Mode of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Canine Atopic Dermatitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Mode of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Canine Atopic Dermatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 8.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 8.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Canine Atopic Dermatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Mode of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Canine Atopic Dermatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Mode of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Canine Atopic Dermatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Mode of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Canine Atopic Dermatitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Mode of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Canine Atopic Dermatitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Mode of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Canine Atopic Dermatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 9.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 9.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Canine Atopic Dermatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Mode of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Canine Atopic Dermatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Mode of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Canine Atopic Dermatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Mode of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Canine Atopic Dermatitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 10.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 10.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Canine Atopic Dermatitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Mode of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Canine Atopic Dermatitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Mode of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Canine Atopic Dermatitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Mode of Administration
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Canine Atopic Dermatitis Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Mode of Administration
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc
• 14.2. Elanco Animal Health Inc
• 14.3. Virbac SA
• 14.4. Toray Industries Inc
• 14.5. AB Science SA
• 14.6. Boehringer Ingelheim GmbH
• 14.7. Kindred Biosciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer